| Name | Title | Contact Details |
|---|
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.
Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Toronto`s Medicine by Design. CCRM is hosted by the University of Toronto and was launched in Toronto`s Discovery District on June 14, 2011.
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities.
Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.